PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
March 1, 2015Pharmacogenomics

Implementation and Evaluation of a CYP2C19 Genotype-Guided Antiplatelet Therapy Algorithm in High-Risk Coronary Artery Disease Patients

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does a CYP2C19 genotype-guided algorithm influence P2Y12 inhibitor selection in high-risk CAD patients undergoing PCI?

Population

264 high-risk coronary artery disease patients receiving percutaneous coronary intervention

Design

Cohort

Authors

JLJohn Andrew LeeCLCraig R. LeeBRBrent N. Reed

Discussion

Loading...

Member takes

Overview

Supports CYP2C19-guided P2Y12 selection post-PCI; hypothesis-generating for genotype-directed strategies, pending randomized outcome trials.

Structured PICO

Does a CYP2C19 genotype-guided algorithm influence P2Y12 inhibitor selection in high-risk CAD patients undergoing PCI?

P
Population
264 high-risk coronary artery disease patients receiving percutaneous coronary intervention
I
Intervention
CYP2C19 genotype-guided antiplatelet therapy algorithm for P2Y12 inhibitor selection
O
Outcome
Factors influencing P2Y12 inhibitor selection and change in therapy

Implementation of a CYP2C19 genotype-guided algorithm is feasible and significantly influences the selection and modification of P2Y12 inhibitor therapy in high-risk PCI patients.

Cite This Study

Lee et al. (2015) studied this question.

synapsesocial.com/papers/6a0fa0c08594bc049cf93331https://doi.org/10.2217/pgs.14.180
View Full Paper
Ask AI
Bookmark
Share